GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » ROC (Joel Greenblatt) %

Cutia Therapeutics (HKSE:02487) ROC (Joel Greenblatt) % : -1,319.25% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cutia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -1,319.25%.

The historical rank and industry rank for Cutia Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:02487' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -813.16   Med: -401.54   Max: -349.33
Current: -813.16

During the past 3 years, Cutia Therapeutics's highest ROC (Joel Greenblatt) % was -349.33%. The lowest was -813.16%. And the median was -401.54%.

HKSE:02487's ROC (Joel Greenblatt) % is ranked worse than
63.54% of 1459 companies
in the Biotechnology industry
Industry Median: -322.46 vs HKSE:02487: -813.16

Cutia Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cutia Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Cutia Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics ROC (Joel Greenblatt) % Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-453.75 -349.33 -831.63

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % - -683.54 -252.43 -1,319.25 -268.53

Competitive Comparison of Cutia Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Cutia Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's ROC (Joel Greenblatt) % falls into.



Cutia Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.109 + 22.33 + 53.073) - (49.066 + 0 + 27.509)
=-1.0629999999999

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.428 + 22.908 + 56.124) - (33.484 + 0 + 25.796)
=24.18

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cutia Therapeutics for the quarter that ended in Jun. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3584.588/( ( (268.178 + max(-1.0629999999999, 0)) + (251.069 + max(24.18, 0)) )/ 2 )
=-3584.588/( ( 268.178 + 275.249 )/ 2 )
=-3584.588/271.7135
=-1,319.25 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutia Therapeutics  (HKSE:02487) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cutia Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics (HKSE:02487) Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Executives
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hsg Holding Limited 2201 Interest of corporation controlled by you
Ma Yun 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Aurora Cutis Limited 2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines